Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32
暂无分享,去创建一个
H. Tagawa | M. Seto | Y. Yatabe | T. Mitsudomi | Y. Sekido | Y. Horio | S. Karnan | T. Fukui | K. Yokoi | T. Taniguchi | T. Yokoyama | Y. Ueda | T. Hida
[1] M. Kondo,et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients , 2006, Cancer science.
[2] Daniel W Lin,et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Naoe,et al. Genomewide array‐based comparative genomic hybridization analysis of acute promyelocytic leukemia , 2006, Genes, chromosomes & cancer.
[4] M. Carbone,et al. The pathogenesis of mesothelioma. , 2006, Seminars in diagnostic pathology.
[5] S. Knuutila,et al. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases , 2006, Virchows Archiv.
[6] B. Robinson,et al. Advances in malignant mesothelioma. , 2005, The New England journal of medicine.
[7] G. Giaccone,et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Papp,et al. Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. , 2005, Oncology reports.
[9] H. Tagawa,et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.
[10] T. Efferth,et al. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines , 2005, Genes, chromosomes & cancer.
[11] M. Jaurand,et al. Pathogenesis of malignant pleural mesothelioma , 2005, Respirology.
[12] H. Tagawa,et al. Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma , 2004, Cancer Research.
[13] Hiroyuki Tagawa,et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.
[14] J. Minna,et al. β-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion , 2003, Oncogene.
[15] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Jun Yokota,et al. Molecular processes of chromosome 9p21 deletions in human cancers , 2003, Oncogene.
[17] W. Schulz,et al. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells , 2003, Genes, chromosomes & cancer.
[18] T. Omasa. Gene amplification and its application in cell and tissue engineering. , 2002, Journal of bioscience and bioengineering.
[19] K. Müller,et al. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases , 2002, The Journal of pathology.
[20] G. Horgan,et al. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .
[21] J. Minna,et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion , 2001, Oncogene.
[22] D. Weiss,et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. , 2001, International journal of oncology.
[23] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[24] J. Testa,et al. Recent advances in the molecular analysis of human malignant mesothelioma. , 2000, La Clinica terapeutica.
[25] W. Dehnen,et al. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. , 2000, Carcinogenesis.
[26] J. Kere,et al. Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis , 1999, British Journal of Cancer.
[27] J. Testa,et al. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma , 1999, Journal of cellular physiology.
[28] F Levi,et al. The European mesothelioma epidemic , 1999, British Journal of Cancer.
[29] S. Jhanwar,et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. , 1999, Cancer research.
[30] W. Kuo,et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.
[31] S. Jhanwar,et al. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. , 1997, Cancer research.
[32] S. Jhanwar,et al. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. , 1996, Cancer research.
[33] K. Pelin,et al. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. , 1996, Cancer genetics and cytogenetics.
[34] S. Jhanwar,et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Fletcher,et al. Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.
[36] J. Minna,et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.
[37] O. Olopade,et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.
[38] S. Jhanwar,et al. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. , 1993, Cancer research.
[39] N. Heintz,et al. Persistent induction of c-fos and c-jun expression by asbestos. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[40] B. Lanphear,et al. Latent period for malignant mesothelioma of occupational origin. , 1992, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[41] R. Metcalf,et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. , 1992, Cancer research.
[42] M. Karin,et al. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.
[43] T. H. van der Kwast,et al. Cytogenetic analysis of malignant mesothelioma. , 1990, Cancer genetics and cytogenetics.
[44] J. Testa,et al. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes , 1989, Genes, chromosomes & cancer.
[45] S. Knuutila,et al. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. , 1988, Cancer genetics and cytogenetics.
[46] R. Stahel,et al. Chromosome changes in malignant mesothelioma. , 1986, Cancer genetics and cytogenetics.
[47] D. Whitaker,et al. The mesothelium and its reactions: a review. , 1982, Critical reviews in toxicology.
[48] Ken Takahashi,et al. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. , 2006, American journal of industrial medicine.
[49] D. Fennell,et al. Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM) , 2006 .
[50] J. Minna,et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] S. Knuutila,et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. , 1998, British Journal of Cancer.
[52] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Knuutila,et al. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. , 1997, British Journal of Cancer.
[54] J. DiPaolo,et al. Nonrandom chromosome alterations in human malignant mesothelioma. , 1988, Cancer research.
[55] Ramon Silva Martins,et al. Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.